Treatment patterns and costs for US type 2 diabetes patients starting tirzepatide or semaglutide who reach treatment goals
Updated
Abstract
Tirzepatide may offer greater hemoglobin A1c and weight reduction compared to other treatments for type 2 diabetes.
- Tirzepatide is a dual receptor agonist targeting insulin and glucagon-like peptides.
- Clinical trials showed superior reductions in hemoglobin A1c and weight compared to comparators.
- It may provide a lower cost per patient reaching treatment goals based on trial-based estimates.
- Real-world data on its comparative effectiveness and economic value remains limited.
Simplified